Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | FPR2 | P25090 | 2/20 | 0.50 |
| ▸ | FPR1 | P21462 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22491682 | 0.86 | ROCK2 (0.49) | PTPN1FPR2FPR1ROCK2RXFP1 | |
| SCHEMBL308869 | 0.85 | PTPN1 (0.59) | PTPN1FPR2FPR1ROCK2USP30 | |
| SCHEMBL1137236 | 0.84 | PTPN1 (0.52) | PTPN1FPR2ROCK2USP30MEN1 | |
| SCHEMBL892417 | 0.84 | HTT (0.54) | PTPN1FPR2FPR1ROCK2USP30 | |
| SCHEMBL892180 | 0.84 | PTPN1 (0.52) | PTPN1FPR2FPR1ROCK2USP30 | |
| SCHEMBL892655 | 0.81 | PTPN1 (0.53) | PTPN1USP30ALDH1A1HDAC8HDAC6 | |
| SCHEMBL892627 | 0.80 | PTPN1 (0.55) | PTPN1ROCK2USP30ROCK1ALDH1A1 | |
| SCHEMBL892757 | 0.80 | HDAC1 (0.53) | PTPN1FPR2FPR1HDAC8HDAC6 | |
| SCHEMBL892246 | 0.80 | HDAC1 (0.52) | PTPN1FPR2ROCK2USP30ROCK1 | |
| SCHEMBL892511 | 0.80 | PTPN1 (0.58) | PTPN1USP30ALDH1A1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313944-A1 | METAP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | Canwell Biotech Limited (HK) | 2024-02-07 | — | — | EP | disclosed |
| CN-117412952-A | METAP-2 inhibitors, pharmaceutical compositions and methods of treatment thereof | 康崴新药有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2022206350-A1 | METAP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | CANWELL BIOTECH LIMITED (CN) | 2022-10-06 | — | — | WO | disclosed |
| US-20030171578-A1 | Pyrrolidinone derivative compound | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-11 | — | — | US | disclosed |
| EP-0916656-B1 | A method for production of pyrrolidinone derivatives | SCHERING AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-6555694-B1 | Reacting an aniline and cyclopropane-1,1-dicarboxylic acid; free of hydrogen-generating substance and moisture sensitive reagent; corrosion resistance; simplification; for piperazine derivatives used as central nervous system disorders | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-29 | — | — | US | disclosed |
| US-6207825-B1 | REACTING THE CORRESPONDING 3-CARBOXYPYRROLIDINONE COMPOUND IN THE PRESENCE OF FORMALDEHYDE | MITSUI CHEMICALS, INC. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0916656-A2 | A method for production of pyrrolidinone derivatives | Mitsui Chemicals, Inc. (JP) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171578-A1 | Pyrrolidinone derivative compound | PFAS, CBR1, PYCR1 | PTPN1 1391/4885FPR2 530/4885FPR1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.